Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ. Holtan SG, et al. Among authors: el jurdi n. J Clin Oncol. 2025 Jan 3:JCO2400921. doi: 10.1200/JCO.24.00921. Online ahead of print. J Clin Oncol. 2025. PMID: 39752608
A contemporary downtrend in chronic GVHD?
El Jurdi N, Pavletic SZ. El Jurdi N, et al. Blood Adv. 2024 Nov 26;8(22):5875-5877. doi: 10.1182/bloodadvances.2024014586. Blood Adv. 2024. PMID: 39546299 Free PMC article. No abstract available.
Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis.
Pidala JA, Kim J, Kalos D, Cutler CS, DeFilipp Z, Flowers ME, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko CL, Ponce DM, Sung AD, Tang H, Farhadfar N, Nemecek ER, Pusic I, Qayed M, Rangarajan HG, Hogan WJ, Etra AM, Jaglowski SM. Pidala JA, et al. Among authors: el jurdi n. Blood Adv. 2024 Oct 25:bloodadvances.2024014374. doi: 10.1182/bloodadvances.2024014374. Online ahead of print. Blood Adv. 2024. PMID: 39454280
Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors.
El Jurdi N, Te HS, Cao Q, Napurski C, Wang S, Robinson A, Arora M, ElHusseini H, He F, Niedernhofer LJ, Thyagarajan B, Prizment A, Holtan S, Blaes AH, Yousefzadeh MJ. El Jurdi N, et al. Aging (Albany NY). 2024 Sep 26;16(18):12432-12442. doi: 10.18632/aging.206109. Epub 2024 Sep 26. Aging (Albany NY). 2024. PMID: 39330993 Free PMC article.
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.
Pidala J, Holtan SG, Walton K, Kim J, Cao B, Elmariah H, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, McSain S, Pleskow J, Baron J, Anasetti C, Moran Segura C, Weisdorf DJ, Blazar BR, Miller JS, Bachanova V, El Jurdi N, Betts BC. Pidala J, et al. Among authors: el jurdi n. Blood. 2024 Nov 28;144(22):2295-2307. doi: 10.1182/blood.2024024789. Blood. 2024. PMID: 39046783 Free PMC article. Clinical Trial.
Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis.
Farhadfar N, Rashid N, Chen K, DeVos J, Wang T, Ballen K, Beitinjaneh A, Bhatt VR, Hamilton BK, Hematti P, Gadalla SM, Solomon SR, El Jurdi N, Lee CJ, MacMillan ML, Rangarajan HG, Schoemans H, Sharma A, Spellman SR, Wingard JR, Lee SJ. Farhadfar N, et al. Among authors: el jurdi n. Blood Adv. 2024 Sep 24;8(18):4963-4976. doi: 10.1182/bloodadvances.2024013074. Blood Adv. 2024. PMID: 38776400 Free PMC article.
77 results